

Biocon Biologics Press Meet

February 28, 2022


Creating a Unique Global, Vertically Integrated Biosimilars Leader

Biocon Biologics: Where We Are Today

Transforming Lives through Meaningful Impact; Touching >3.6 mn^ Patients' Lives

Driven with a **sense of purpose**
to **enable equitable access** to
high quality **biologics**


Global Biosimilars Business
with **annual revenue** of
USD 384 million*




Leveraging **cutting-edge science**,
advanced technology platforms,
global scale bio-manufacturing

Expanding access to
Comprehensive biologics
Portfolio through **global**
partnerships

Biosimilars: Attractive Global Opportunity



Source: IQVIA Forecast Link, Dec 2021; Historical data to Q2 2021




**A Technology-Led Journey to
Enable Affordable Healthcare**


Unlocking Value Over the Years



Biocon has benefited from transformational moves every decade



Pioneering Several Firsts in the Area of Biosimilars



Biocon Biologics to Acquire Viatris' Biosimilars Assets

Combination Creates a Unique Global, Vertically
Integrated Biosimilars Leader

Strong Strategic Rationale for Acquisition of Viatriss' Global Biosimilars Business



BBL to emerge as a unique global, vertically integrated biosimilars leader

BBL will realize full revenues & profits from acquired business

Accelerates BBL's direct commercialization strategy; making it future-ready

**BBL will have largest & deepest biosimilars portfolio;
20 Biosimilars**

Deal to be value accretive to Biocon and BBL shareholders

Fast tracks BBL's journey of building a strong global brand

BBL to Acquire A Strong Global Biosimilars Business




Estimated Revenue Of
Acquired **Biosimilars**
Business
USD 1 billion
next year

Biocon Biologics: To be A Fully Integrated Biosimilars Enterprise



- Acquires Commercial Engine For Global Markets
- Strengthens Global Regulatory & Clinical Capabilities
- Enhances Ability to Mitigate Pricing Pressure, Growing Competition
- Increases Agility For Operational Efficiencies



Acquisition Brings Together Complementary Capabilities and Strengths



CURRENT

Emerging Markets

Developed Markets

POST ACQUISITION

Global markets

PRODUCT DEVELOPMENT



CLINICAL TRIALS



REGULATORY



MANUFACTURING



SUPPLY CHAIN



COMMERCIALIZATION



Acquired Biosimilars Business to Add Financial Depth and Commercial Capabilities



Viatrix to provide commercial and transition services for an expected two-year period, at cost plus \$44m p.a.

Full Ownership of Partnered Biosimilars Portfolio, Including In-licensed Assets

- BBL will realize **full revenue and associated profits** from its partnered products
- Comprehensive biosimilar insulins portfolio, including **rh-Insulin**, **bGlargine** and **bAspart**;
- Growing biosimilar oncology portfolio, including **bTrastuzumab**, **bBevacizumab**, **bPegfilgrastim**;
- Significant presence in autoimmune segment through in-licensed products like **bAdalimumab**[^], **bEtanercept**[^]



[^]In-licensed by Viatrix

BBL's Comprehensive Product Portfolio Will Provide Global Scale & Fuel Future Growth

One of the Broadest & Deepest Biosimilars Pipelines Globally

Today

- bPegfilgrastim
- bTrastuzumab
- bBevacizumab (EU)
- bGlargine 100 IU
- bAspart (EU)
- bAdalimumab (EU)
- bEtanercept (EU)

< 2 years

- bBevacizumab (US)
- bAspart (US)
- bAdalimumab (US)
- rH-Insulin (US)
- **Vaccines** (*SILS collaboration*)

2-4 years

- bAflibercept
- Two undisclosed programs

>4 years

- bPertuzumab
- bGlargine 300 IU
- Seven undisclosed programs

07

Commercialized in Global Markets

20



Biosimilars in our Portfolio

Expand Geographic Reach; Accelerate Build out of Commercial Capability in Developed Markets

Accelerates BBL's Direct Commercialization Strategy: Takes us Closer to Patients & Customers;
Will Help BBL become a Strong Global Brand




Regulatory, Supply Chain & Commercial
Capabilities in
Developed Markets




Biosimilars R&D, Manufacturing &
Commercial Presence in Key
Emerging Markets





Transaction Details


Considerations to Viatris: Will Receive up to USD 3.335 billion in Cash & Stock




Viатris will have one nominee on the Board of Biocon Biologics

*CCPS : Compulsorily Convertible Preference Shares equivalent to equity stake of at least 12.9% on a fully diluted basis

Financing the Acquisition



Deal to Provide Seamless Transition




Viartis will provide transition services for 2 years, ensuring continued services to patients, customers



Transaction is expected to close in the H2 2022



Minimal overlap of roles in 2 organizations due to complementary nature of teams



Kiran Mazumdar-Shaw will continue as the Executive Chairperson of BBL



Viartis will designate Rajiv Malik, President of Viartis, on the BBL Board

Building an Organization for The Future

1

Fully Integrated Global Biosimilars Company With Global Scale And Reach

2

Strong Commercial Presence In Both Developed And Emerging Markets

3

Comprehensive Portfolio Of Biosimilars And Vaccines With Clear Growth Path

4

Large-scale Biologics Manufacturing Capacity With End-to-end Capabilities

5

Highly Experienced Management Team To Build the Organization of the Future

6

Robust Financials Enabling Continued Investments For Long-term Growth

Transforming Healthcare. Transforming Lives.

